http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-102307-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1cd7029ec038fa78d4b371f9bf08e9e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 |
| filingDate | 2015-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a699810591306b0f07497cc7448d6e84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f81c81e03cd7f5c67f0a6578f306fe1 |
| publicationDate | 2017-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-102307-A1 |
| titleOfInvention | COMPOSITIONS OF CARING PROTEINS - ANTIBODIES AND METHODS FOR THEIR ELABORATION AND USE |
| abstract | Compositions of antibodies and carrier proteins and methods for their elaboration and use, in particular, in cancer therapy. Freeze-dried compositions of antibodies and carrier proteins and methods for their elaboration and use, in particular, in cancer therapy. Claim 9: The lyophilized nanoparticle composition of any of the preceding claims, characterized in that the antibodies are selected from the group consisting of ado-trastuzumab emtansine, alemtuzumab, bevacizumab, cetuximab, denosumab, dinutuximab, ipilimumab, nivolumab, obinumumab, ofatumumab, ofatumumab, ofatumumab, ofatumumab, of , pembrolizumab, pertuzumab, rituximab and trastuzumab. Claim 10: The lyophilized nanoparticle composition of any one of the preceding claims, characterized in that said at least one therapeutic agent is selected from the group consisting of abiraterone, bendamustine, bortezomib, carboplatin, cabazitaxel, cisplatin, chlorambucil, dasatinib, docetaxel, doxorubicin , epirubicin, erlotinib, etoposide, everolimus, gefitinib, idarubicin, imatinib, hydroxyurea, imatinib, lapatinib, leuprorelin, melphalan, methotrexate, mitoxantrone, nedaplatin, nilotinib, oxaliplatin, paclitaxel, pazopanib, pemetrexed, picoplatin, romidepsin, satraplatin, sorafenib, vemurafenib , sunitinib, teniposide, triplatin, vinblastine, vinorelbine, vincristine and cyclophosphamide. Claim 11: The lyophilized nanoparticle composition of any one of the preceding claims, characterized in that the carrier protein is selected from the group consisting of albumin, gelatin, elastin, gliadin, legumine, zein, a soy protein, a milk protein and a protein of serum Claim 21: A lyophilized nanoparticle composition, characterized in that it comprises nanoparticles, wherein each of the nanoparticles comprises: a) a paclitaxel core bound to albumin and b) between about 400 and about 800 bevacizumab molecules arranged on a core surface of albumin-bound paclitaxel such that the antibody binding portion is directed outwardly with respect to said surface, wherein the antibodies retain their association with the nanoparticle surface after reconstitution with an aqueous solution, provided that said composition Lyophilized is stable at a temperature between about 20 ° C and about 25 ° C for at least 3 months and the reconstituted nanoparticles can be attached to VEGF in vivo. Claim 34: The nanoparticle composition of claim 32 or 33, characterized in that said at least one additional therapeutic agent is selected from the group consisting of abiraterone, bendamustine, bortezomib, carboplatin, cabazitaxel, cisplatin, chlorambucil, dasatinib, docetaxel, doxorubicin , epirubicin, erlotinib, etoposide, everolimus, gemcitabine, gefitinib, idarubicin, imatinib, hydroxyurea, imatinib, lapatinib, leuprorelin, melphalan, methotrexate, mitoxantrone, nedaplatin, nilotinib, oxalipratin platinum, phenoxylatin, phenoxyplatin, venipratinopaptin, venipratinopaptin, venipratinopaptin, venipratinopaptin, venipratinopaptin, venipratinopaptin, venipratinopaptin, venipratin, venipratinopaptin, venomophenolidene , sunitinib, teniposide, triplatin, vinblastine, vinorelbine, vincristine and cyclophosphamide. |
| priorityDate | 2015-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 126.